What does the evidence say about Olive Oil Cardiometabolic Markers Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Olive Oil Cardiometabolic Markers Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - This cross-sectional study analysed whether metabolic profile modifies the associations between chocolate consumption and cardiometabolic risk markers in 1960 adults from the SALMANTICOR population-based cohort. [Martín-Carro B (2026); evidence level 4] - In multivariable models without interaction terms, both dark and milk chocolate consumption were associated with lower BMI, whereas dark chocolate consumption was associated with higher LDL cholesterol. [Martín-Carro B (2026); evidence level 4] - Among individuals with diabetes, dark chocolate consumption was associated with lower fasting glucose and HbA1c, whereas milk chocolate consumption was associated with lower HbA1c compared with non-consumption. [Martín-Carro B (2026); evidence level 4] - Background/Objectives : Studies evaluating the association between chocolate consumption and cardiometabolic health have reported inconsistent findings, and whether these associations differ according to underlying metabolic status remains unclear. [Martín-Carro B (2026); evidence level 4] - Olive oil, particularly virgin (VOO) and extra-virgin olive oil (EVOO), is a central component of the Mediterranean diet and has been associated with cardiometabolic, anti-inflammatory, and intestinal health benefits. [Barrera-Chamorro L (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.